Floatz logo

Masitinib

Metastatic Colorectal Cancer

AB ScienceSmall moleculePhase 3Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
65/ 100

Competitive context

120 Active assets in the Metastatic Colorectal Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB
Eloxatin
Allama Iqbal Medical College
Phase 3BB
Regorafenib
China Medical University, China
Phase 4BB

View all 50 →

Same molecule, other indications

Masitinib is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
castration-resistant prostate carcinomaDormant
B
Indicative ·
62 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →